Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia.
about
Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerationsBosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.Improvement of pyrazolo[3,4-d]pyrimidines pharmacokinetic properties: nanosystem approaches for drug delivery.Advances in studies of tyrosine kinase inhibitors and their acquired resistance.
P2860
Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia.
@en
type
label
Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia.
@en
prefLabel
Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia.
@en
P2860
P356
P1476
Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia.
@en
P2093
Fuad El Rassi
Hanna Jean Khoury
P2860
P356
10.2147/PGPM.S32145
P577
2013-08-05T00:00:00Z